Anika Therapeutics Inc. Common Stock (NASDAQ:ANIK)

Real-time price: | Most recent change:0.00%

Anika Therapeutics, Inc. is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. Anika's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration....

+See More


Here we provide our AYA proprietary alpha stock signals for all premium members on our AYA fintech network platform. Specifically, a high Fama-French multi-factor dynamic conditional alpha suggests that the stock is likely to consistently outperform the broader stock market benchmarks such as S&P 500, Dow Jones, Nasdaq, Russell 3000, MSCI USA, and MSCI World etc. Since March 2023, our proprietary alpha stock signals retain U.S. Patent and Trademark Office (USPTO) fintech patent protection, approval, and accreditation for 20 years. Our homepage and blog articles provide more details on this proprietary alpha stock market investment model with robust long-term historical backtest evidence.

Sharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 18 April 2026

Blog+More

Stock Synopsis: Pharmaceutical post-pandemic patent development cycle

John Fourier

2024-05-05 10:31:00 Sunday ET

Stock Synopsis: Pharmaceutical post-pandemic patent development cycle

Stock Synopsis: Pharmaceutical post-pandemic patent development cycle In terms of stock market valuation, the major pharmaceutical sector remains at its

+See More

President Trump hails and touts America's new high real GDP economic growth in mid-2018.

Daisy Harvey

2018-07-25 11:41:00 Wednesday ET

President Trump hails and touts America's new high real GDP economic growth in mid-2018.

President Trump hails and touts America's new high real GDP economic growth in 2018Q2. The U.S. is now a $20+ trillion economy, and America hits this mi

+See More

Global stock market investors foresee the harbinger of a major economic downturn.

Monica McNeil

2019-09-17 08:33:00 Tuesday ET

Global stock market investors foresee the harbinger of a major economic downturn.

Global stock market investors foresee the harbinger of a major economic downturn. Many stock market investors become anxious due to negative term spreads an

+See More

Agile lean enterprises break down organizational silos to promote smart collaboration for better profitability and customer loyalty.

Laura Hermes

2020-11-03 08:30:00 Tuesday ET

Agile lean enterprises break down organizational silos to promote smart collaboration for better profitability and customer loyalty.

Agile lean enterprises break down organizational silos to promote smart collaboration for better profitability and customer loyalty. Heidi Gardner (2017

+See More

Ben Horowitz shares many hard truths, setbacks, failures, obstacles, difficulties, and disappointments through his rare unique entrepreneurial journey at LoudCloud.

Laura Hermes

2025-05-29 08:25:28 Thursday ET

Ben Horowitz shares many hard truths, setbacks, failures, obstacles, difficulties, and disappointments through his rare unique entrepreneurial journey at LoudCloud.

Serial venture capitalist Ben Horowitz describes many hard truths, lessons, and insights from his entrepreneurial journey of running LoudCloud from a Silico

+See More

Amazon faces E.U. antitrust scrutiny over the current e-commerce use of merchant data.

Olivia London

2019-08-16 17:37:00 Friday ET

Amazon faces E.U. antitrust scrutiny over the current e-commerce use of merchant data.

Amazon faces E.U. antitrust scrutiny over the current e-commerce use of merchant data. The European Commission probes into whether Amazon uses key third-par

+See More